Pesquisa | SciELO

Abstract Recent studies have reported the occurrence of thrombotic phenomena or coagulopathy in patients with COVID-19. There are divergent positions regarding the prevention, diagnosis, and treatment of these phenomena, and current clinical practice is based solely on deductions by extension from retrospective studies, case series, observational studies, and international guidelines developed prior to the pandemic. In this context, the aim was to generate a group of recommendations on the prevention, diagnosis and management of thrombotic complications associated with COVID-19. Methods: A rapid guidance was carried out applying the GRADE Evidence to Decision (EtD) frameworks and an iterative participation system, with statistical and qualitative analysis. Results: 31 clinical recommendations were generated focused on: a) Coagulation tests in symptomatic adults with suspected infection or confirmed SARS CoV-2 infection; b) Thromboprophylaxis in adults diagnosed with COVID-19 (Risk scales, thromboprophylaxis for outpatient, in-hospital management, and duration of thromboprophylaxis after discharge from hospitalization), c) Diagnosis and treatment of thrombotic complications, and d) Management of people with previous indication of anticoagulant agents. Conclusions: Recommendations of this consensus guide clinical decision-making regarding the prevention, diagnosis, and treatment of thrombotic phenomena in patients with COVID-19, and represent an agreement that will help decrease the dispersion in clinical practices according to the challenge imposed by the pandemic.

Abstract Introduction: recent studies have reported the occurrence of thrombotic phenomena or coagulopathy in patients with COVID-19. There are divergent positions regarding the prevention, diagnosis, and treatment of these phenomena, and current clinical practice is based solely on deductions by extension from retrospective studies, case series, observational studies, and international guidelines developed prior to the pandemic. Objective: to generate a group of recommendations on the prevention, diagnosis and management of thrombotic complications associated with COVID-19. Methods: a rapid guidance was carried out applying the GRADE Evidence to Decision (EtD) frameworks and an iterative participation system, with statistical and qualitative analysis. Results: 31 clinical recommendations were generated focused on: a) Coagulation tests in symptomatic adults with suspected infection or confirmed SARS CoV-2 infection; b) Thromboprophylaxis in adults diagnosed with COVID-19 (Risk scales, thromboprophylaxis for outpatient, in-hospital management, and duration of thromboprophylaxis after discharge from hospitalization), c) Diagnosis and treatment of thrombotic complications, and d) Management of people with previous indication of anticoagulant agents. Conclusions: recommendations of this consensus guide clinical decision-making regarding the prevention, diagnosis, and treatment of thrombotic phenomena in patients with COVID-19, and represent an agreement that will help decrease the dispersion in clinical practices according to the challenge imposed by the pandemic.

Objective. To determine the relationship between the degree of addiction (DA) and pattern of tobacco consumption (PTC) with anxiety and depression in smokers who want to quit smoking. Material and Methods. At admission to a smoking cessation program 495 smokers were surveyed to determine anxiety (IDARE Test), depression (Beck Inventory Test), DA (Fagerström Test) and PTC (pack-years). Results. DA>= 6 points was associated with high anxiety levels RM=1.94, (IC95%1.02-3.72), p<0.04]; and with symptoms of severe depression; [RM=2.24, (IC95%1.00-4.99), p<0.04)]. The PCT equal or greater than 21 pack-year, was associated with moderate anxiety; [RM=3.19 (IC95%1.94-5.25), p<.00]; high anxiety; [RM=3.36 (IC95% 1.66-6-80), p<.00]; with moderate depressive symptoms; [RM=3.14, (IC95% 1.75-5-62), p<.00] and severe depressive symptoms; [RM=9.85, (IC95% 3.30-29.37), p<.00)]. Conclusion. A significant association exists in smokers having high GA and PCT, with moderate and high anxiety and depressive symptoms that should be considered during interventions to quit.

Objetivo. Determinar la asociación entre el grado de adicción (GA) y patrón de consumo de tabaco (PCT) con la ansiedad y depresión en fumadores que quieren dejar de fumar (FQDF). Material y métodos. En 495 sujetos que acudieron a un programa para dejar de fumar se determinó la ansiedad (inventario IDARE) y depresión (cuestionario BECK), el GA (cuestionario de Fagerström) y PCT (paquetes-año). Resultados. El GA>= a 6 puntos se asoció con niveles de ansiedad altos [RM=1.94, (IC95%1.02-3.72), p<0.04] y con síntomas de depresión graves [RM=2.24, (IC95%1.00-4.99), p<0.04)]. El PCT>= a 21 paquetes año, se asoció con ansiedad rasgo media; [RM=3.19 (IC95%1.94-5.25), p<.00]; ansiedad rasgo alta; [RM=3.36 (IC95% 1.66-6-80), p<.00]; con depresión moderada; [RM=3.14, (IC95% 1.75-5-62) p<.00] y depresión grave; [RM=9.85, (IC95% 3.30-29.37), p<.00)]. Conclusión. Existe una asociación significativa en fumadores con alto GA y PCT, con la presencia de ansiedad y síntomas de depresión moderada a grave que deben considerarse en FQDF.

Cód. do Índice	Elemento
ti	título do artigo
au	autor
kw	palavras-chave do artigo
subject	assunto (palavras do título, resumo e palavras-chave)
ab	resumo
ta	título abreviado da revista (ex. Cad. Saúde Pública)
journal_title	título completo da revista (ex. Cadernos de Saúde Pública)
la	código do idioma da publicação (ex. pt - Português, es - Espanhol)
type	tipo do documento
pid	identificador da publicação
publication_year	ano de publicação do artigo
sponsor	financiador
aff_country	código do país de afiliação do autor
aff_institution	instituição de afiliação do autor
volume	volume do artigo
issue	número do artigo
elocation	elocation
doi	número DOI
issn	ISSN da revista
in	código da coleção SciELO (ex. scl - Brasil, col - Colômbia)
use_license	código da licença de uso do artigo

Não foram encontrados documentos para sua pesquisa